This activity will address knowledge and practice gaps related to combination medication therapy for patients with diabetes. Clinicians will be instructed on the rationale and benefits for combining a GLP-1 receptor agonist (GLP-1 RA) with basal insulin, the differences between short-acting and long-acting GLP-1 RAs, and the safety and efficacy for combining a GLP-1 RA and basal insulin including emerging fixed-ratio formulations. Additionally, clinicians will have the opportunity to apply their knowledge by demonstrating when and in whom to use combination therapy of GLP-1 RA and basal insulin.
- Describe the rationale and benefits for combining a GLP-1 RA with basal insulin.
- Outline the differences between short-acting and long-acting GLP-1 RAs.
- Discuss guideline recommendations for when and in whom to use combination therapy of a GLP-1 RA and basal insulin.
- Summarize the safety and efficacy for combining a GLP-1 RA and basal insulin, including the role of emerging fixed-ratio formulations.
This CME initiative is designed for Endocrinologists, Endocrine Fellows, and other clinicians who care for patients with type 2 diabetes.
Dace L. Trence, MD, FACE, is currently Director of the Diabetes Care Center and Professor of Medicine at the University of Washington Medical Center in Seattle. She is also the University of Washington Endocrine Fellowship Program Director and Director of Endocrine Days, a medical education program for endocrinologists practicing in the Pacific Northwest. She currently serves on the American Association of Clinical Endocrinologists Board of Directors, chairing the AACE Publications Committee and co-chairing AACE CME committee. She has been on the editorial boards of several journals including Clinical Diabetes. She has had articles published in JCEM, JAMA, Diabetes Care and is a co-author of Optimizing Diabetes Care for the Practitioner. Her current interests include improving educational processes in diabetes self-management and clinical training of health care professionals.
This activity was launched on November 14, 2016 and will expire on November 1, 2017.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
How To Claim Credit
By reviewing the course content and successfully completing the pre-test, post-test and evaluation, physicians are entitled to receive a maximum of 1.0 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the pre-test and activity evaluation.
• Pass the post-test (2 of 3 correct).
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members’ relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Dr. Trence has stock/bond holdings in Sanofi and Medtronic.
Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, OR provided external review for this activity.
Dr. Jessica Castle has served on an Advisory Board for Novo Nordisk.
Others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any commercial interests.
Program supported by an educational grant from Sanofi US.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.